| Similar Articles |
|---|
 |
The Motley Fool
February 24, 2011
Brian Orelli |
Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.   |
Fast Company
April 2012
Christina Chaey |
Stevi Riel Provides Partnerships With Hospitals To Find Affordable Help For Patients This year, the U.S. government started a program for health-care innovators. One innovator, Stevi Riel takes what physicians are too busy to do, and partners with hospitals to find affordable prescription solutions for underinsured patients. |
Science News
March 28, 2009 |
Science Past For March 28, 1959 Thoughts on patient resocialization in a mental hospital during the 1950s. |
BusinessWeek
February 4, 2010 |
How Disease Management Works Providers have convinced many big employers that their services save money and improve employee health. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Inc.
June 2009
Nicole Marie Richardson |
Innovation: CardioMEMS EndoSure Sensor CardioMEMS creates body sensors that monitor cardiovascular health. |
Pharmaceutical Executive
March 1, 2013
Al Topin |
Less Selling, More Time What can happen when pharmaceutical reps focus on the physician-patient conversation? |
Fast Company
September 14, 2011
Emma Haak |
Global E-Health Forum Protecting patients' medical information in the digital age is no easy feat. |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
The Motley Fool
November 18, 2010
Brian Orelli |
Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge. |
The Motley Fool
July 1, 2011
Brian Orelli |
Dendreon Is Drama-Free ... for Now For a drug that has had so much drama during its existence, the final decision by the Centers for Medicare and Medicaid Services to pay for Dendreon's prostate cancer treatment Provenge was pretty anticlimactic. |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
CIO
September 27, 2013 |
How IT Can Produce Better Patient Care For Dr. Bob Laskowski, president and CEO of Christiana Care Health System, technology means empowering physicians and patients. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
IEEE Spectrum
June 2010
Prachi Patel |
Diagnostic Contacts A contact lens that tracks ocular pressure may help treat glaucoma |
Managed Care
February 2002
Heidi A. Sauder & Sheri Wallace |
Push Is On for Improved Treatment of Women's Psychological Maladies Sure there are diagnostic and treatment challenges, but the money that can be saved for society might make this fertile ground for investment... |
The Motley Fool
August 11, 2010
Brian Orelli |
Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients. |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
The Motley Fool
March 30, 2011
Brian Orelli |
Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
Pharmaceutical Executive
October 1, 2010 |
Optimizing TV Advertising Placements & Results Brand managers choosing to advertise an anti-depressant on "Criminal Minds" may not be making the best choice. New methodologies reveal "Law & Order: Special Victims Unit" along with "The Bachelor" to be shows favored by depressives. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
American Journal of Nursing
September 2011
Adams & Tolich |
Original Research: Blood Transfusion: The Patient's Experience This study therefore sought to identify how well patients understand the role of blood transfusion in their treatment and whether it causes them discomfort. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
CIO
October 29, 2015
Martha Heller |
Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies. |
Pharmaceutical Executive
August 1, 2011
Jennifer Ringler |
The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout? |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
Pharmaceutical Executive
November 1, 2012
Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
Managed Care
May 2000 |
Arizona Nixes Doc Incentives, OKs Plan Liability The publicity given to the Texas attorney general's agreement with Aetna overshadowed a more sweeping edict in Arizona regarding financial incentives to physicians.... |
Fast Company
April 2012
Tara Moore |
Diane Curley Is Starting The Conversation To Curb Obesity This year, the U.S. government started a program for health-care innovators. One innovator, Diane Curly is treating obesity like any other disease or addiction and trains nurses to talk to patients about treatment. |
InternetNews
July 27, 2010 |
FDA, FCC Push For Wireless Health Technology The government agencies are teaming up to use the latest and greatest wireless technology to improve care and reduce healthcare costs using electronic health records. |
The Motley Fool
June 2, 2011
Luke Timmerman |
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources? |
The Motley Fool
February 22, 2011
Brian Orelli |
Biogen and Elan's Growing Problem More cases of potentially lethal PML. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
Pharmaceutical Executive
May 1, 2009
Maryann Kuzel |
Weathering the Storm Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market. |
Managed Care
April 2000
Michael S. Victoroff, M.D. |
Helping Marginally Covered May Take Public-Private Effort Opening medicine's doors to a broader population has invoked the law of unintended consequences. Primary care physicians feel an increased demand for visits, referrals, and advice. ... |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
American Family Physician
March 15, 2007
Freedy & Simpson |
Disaster-Related Physical and Mental Health: A Role for the Family Physician Family physicians should be prepared to work with other health care professionals in the community to share the collective load in meeting post-disaster health needs; such partnerships should be established well in advance of a disaster. |
